Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug

Japan's Takeda disclosed recently that Swiss partner Santhera has commenced a pivotal Phase III trial for Catena/Sovrima (idebenone), which could be the first drug to treat Duchenne Muscular Dystrophy, a rare disease that affects an estimated 30,000 European and North American male patients mainly in their teens

More from Archive

More from Scrip